Date Time
Novel guidelines help select optimal deconvolution method
Biomedical scientists are increasingly using deconvolution methods, those used to computationally analyze the composition of complex mixtures of cells. One of their challenges is to select one method that is appropriate for their experimental conditions among nearly 50 available.
To help with method selection, researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital have extensively evaluated 11 deconvolution methods that are based on RNA-sequencing (RNA-seq) data analysis, determining each method’s individual strengths and weaknesses in a variety of scenarios. From these analyses, the researchers derived guidelines that scientists can use to determine the deconvolution method that optimally fits their needs. The study appears in the journal Genome Biology.
Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors
Data provides springboard to advance three additional clinical programs evaluating Tegavivint in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC) and pediatric cancers
News provided by
Share this article
Share this article
HOUSTON, April 13, 2021 /PRNewswire/ Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has confirmed the safety of Tegavivint, a novel, potent and selective nuclear beta-catenin inhibitor, after completing enrollment and dosing the final patient in a multicenter Phase 1/2a dose expansion clinical study of Tegavivint in patients with desmoid tumors.
Novel guidelines help select optimal deconvolution method eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Date Time
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to promote metastasis and tumor growth. Blocking CREB1 in preclinical models reversed these effects and reduced metastases, suggesting an important new therapeutic target for the deadly cancer.
“To our knowledge, this is the first study to show how these two major genetic drivers work together to promote tumor growth and metastasis,” Kim said. “We learned that signaling downstream of mutant KRAS directly promotes mutant p53 activity. This discovery provides not only a new therapeutic target but unveils a vast transcriptional network that is activated downstream of these mutant proteins.”
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.